Davita earnings release, August 4, 2026

Davita Inc. (DVA) · Form 8-K, Item 2.02 · Filed · SEC filing

Contact: Investor Relations

DaVita Inc. ir@davita.com

DaVita Inc. 2nd Quarter 2026 Results

Denver, Colorado, August 4, 2026 — DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended June 30, 2026.

“Thanks to the outstanding efforts of our teammates, we had another positive quarter for both patient outcomes and financial results,” said Javier Rodriguez, CEO of DaVita Inc. “As we look to the rest of the year, we maintain our strategic focus on exciting new innovations in kidney dialysis to enhance the lives of our patients.”

Financial and operating highlights for the quarter ended June 30, 2026:

• Consolidated revenues were $3.554 billion.

• Operating income was $579 million.

• Diluted earnings per share was $4.02.

• Operating cash flow was $490 million and free cash flow was $256 million.

• Incurred an incremental Term Loan B-2 tranche in the aggregate principal amount of $500 million and used a portion of the proceeds to repay a portion of the balance then outstanding on our revolving line of credit.

• Repurchased 2.2 million shares of the Company's common stock at an average price paid of $154.95 per share.

(1)

For definitions of non-GAAP financial measures, see the note titled "Note on Non-GAAP Financial Measures" and related reconciliations beginning on page¹⁴.

(1)

For definitions of non-GAAP financial measures, see the note titled "Note on Non-GAAP Financial Measures" and related reconciliations beginning on page¹⁴.¹

U.S. dialysis metrics:

Volume:

Total U.S. dialysis treatments for the second quarter of 2026 were 7,226,600, or an average of 92,649 treatments per day, representing a per day increase of 1.09% compared to the first quarter of 2026. Normalized non-acquired treatment growth in the second quarter of 2026 compared to the second quarter of 2025 was 0.3%.

Primary drivers of the changes in the table above were as follows:

Revenue:

The quarter change was primarily driven by changes in payor mix and other normal fluctuations partially offset by seasonal impact of co-insurance and deductibles and an increase in average rates. The year to date change was driven by typical annual increases, including Medicare base rate and other normal fluctuations, partially offset by changes in payor mix.

Patient care costs:

The quarter change was primarily due to decreases in payroll taxes and pharmaceutical costs, partially offset by increased health benefits expenses. Additionally, our fixed direct operating expenses favorably impacted patient care costs per treatment due to increased treatments in the second quarter. The year to date change was primarily driven by increased compensation expenses, insurance costs and health benefits expenses.

General and administrative:

The quarter change was primarily due to increased professional fees. The year to date change was primarily driven by increases in IT-related costs and compensation expenses partially offset by costs related to the cybersecurity incident experienced by the Company in 2025.

Certain items impacting the quarter:

Debt transaction.

In June 2026, we entered into the Ninth Amendment to our senior secured credit agreement. The Ninth Amendment extends an incremental Term Loan B-2 tranche in the aggregate principal amount of $500 million. A portion of the net proceeds from this transaction was used to repay a portion of the balance outstanding on our revolving line of credit and related accrued interest and fees. The remaining borrowings added cash to the balance sheet for general corporate purposes.

Share repurchases.

During the three months ended June 30, 2026, we repurchased 2.2 million shares for $348 million, at an average price paid of $154.95 per share.

Subsequent to June 30, 2026 through August 4, 2026, the Company has repurchased 0.2 million shares of our common stock for $37 million at an average price paid of $199.55 per share.

Financial and operating metrics:

(1)

For definitions of non-GAAP financial measures, see the note titled "Note on Non-GAAP Financial Measures" and related reconciliations beginning on page¹⁴.²

(1)

For definitions of non-GAAP financial measures, see the note titled "Note on Non-GAAP Financial Measures" and related reconciliations beginning on page¹⁴.

Center activity:

As of June 30, 2026, we provided dialysis services to a total of approximately 298,500 patients at 3,266 outpatient dialysis centers, of which 2,671 centers were located in the United States and 595 centers were located in 14 countries outside of the United States.

Integrated kidney care (IKC):

As of June 30, 2026, we had approximately 64,900 patients in risk-based integrated care arrangements representing approximately $5.8 billion in annualized medical spend. We also had an additional 5,700 patients in other integrated care arrangements; we do not include the medical spend for these patients in this annualized medical spend estimate. For an additional description of these metrics, see footnote 5 in the "Supplemental Financial Data" table below.

Outlook:... (truncated)ted income attributable to DaVita Inc. also excludes the amount of third-party owners' income and related taxes attributable to non-tax paying entities.

The following table outlines normalized treatment days by quarter for 2025 and 2026. Normalized treatment days are adjusted for the mix of days of the week for each quarter and serve as a means to more readily compare calendar effects on each quarter's treatment volume.

Certain columns, rows or percentages may not sum or recalculate due to the presentation of rounded numbers.

We will be holding a conference call to discuss our results for the second quarter ended June 30, 2026, on August 4, 2026, at 5:00 p.m. Eastern Time. To join the conference call, please dial (877) 918-6630 from the U.S. or (517) 308-9042 from outside the U.S., and provide the operator the password "Earnings." This call is being webcast and can be accessed at the DaVita Investor Relations website investors.davita.com. A replay of the conference call will also be available at investors.davita.com.³

Forward looking statements

Financial statements

Income Statement

Three months ended — For definitions of non-GAAP financial measures, see the note titled "Note on Non-GAAP Financial Measures" and related reconciliations beginning on page 14 . (in millions)

Three months ended – June 30, 2026 – AmountThree months ended – June 30, 2026 – MarginThree months ended – March 31, 2026 – AmountThree months ended – March 31, 2026 – MarginSix months ended June 30, – 2026 – AmountSix months ended June 30, – 2025 – MarginSix months ended June 30, – 2025 – AmountSix months ended June 30, – Margin
Operating income57916.348214.11,06115.297714.8
Adjusted operating income(1)57916.348214.11,06115.299015

Income Statement (dollars in millions, except per share data)

Current 2026 guidance – LowCurrent 2026 guidance – High
Adjusted operating income2,1502,250
Adjusted diluted net income per share attributable to DaVita Inc.14.115.2
Free cash flow1,0001,250

Income Statement

Three months ended June 30, — (dollars and shares in thousands, except per share data)

Three months ended June 30, – 2026Three months ended June 30, – 2025Six months ended June 30, – 2026Six months ended June 30, – 2025
Dialysis patient service revenues3,366,3773,206,8716,639,1746,309,864
Other revenues187,707172,655330,458293,191
Total revenues3,554,0843,379,5266,969,6326,603,055
Operating expenses:Patient care costs2,392,0012,261,5404,734,2584,501,200
Operating expenses:General and administrative423,458412,805845,372786,895
Operating expenses:Depreciation and amortization167,808174,704345,637351,155
Operating expenses:Equity investment income, net-8,184-7,364-16,528-12,973
Operating expenses:Total operating expenses2,975,0832,841,6855,908,7395,626,277
Operating expenses:Operating income579,001537,8411,060,893976,778
Operating expenses:Debt expense-150,256-146,062-295,387-281,117
Operating expenses:Debt extinguishment and modification costs-2,035-2,035
Operating expenses:Other income (loss), net8,300-22,85112,773-40,400
Operating expenses:Income before income taxes435,010368,928776,244655,261
Operating expenses:Income tax expense91,78793,708157,986147,825
Operating expenses:Net income343,223275,220618,258507,436
Operating expenses:Less: Net income attributable to noncontrolling interests-77,826-75,883-155,331-145,182
Operating expenses:Net income attributable to DaVita Inc.265,397199,337462,927362,254
Earnings per share attributable to DaVita Inc.:Basic net income4.12.627.014.67
Earnings per share attributable to DaVita Inc.:Diluted net income4.022.586.864.57
Weighted average shares for earnings per share:Basic shares64,78175,94366,07877,646
Weighted average shares for earnings per share:Diluted shares66,09277,36267,47679,309

Income Statement

Three months ended — (unaudited) (dollars in millions and shares in thousands, except per treatment and patient data)

Three months ended – June 30, 2026Three months ended – March 31, 2026Six months ended June 30, 2026
1. Consolidated business metrics:Operating margin16.314.115.2
1. Consolidated business metrics:General and administrative expenses as a percent of consolidated revenues(2)11.912.412.1
1. Consolidated business metrics:Effective income tax rate on income21.119.420.4
1. Consolidated business metrics:Effective income tax rate on income attributable to DaVita Inc.(1)25.625.125.4
Revenues:U.S. dialysis patient services and other3,0122,9425,954
Other—Ancillary servicesIntegrated kidney care162116278
Other—Ancillary servicesOther U.S. ancillary91019
Other—Ancillary servicesInternational dialysis patient service and other386372758
Other—Ancillary services5574981,054
Other—Ancillary servicesEliminations-14-24-38
Other—Ancillary servicesTotal consolidated revenues3,5543,4166,970
Operating income (loss):U.S. dialysis5385061,044
Other—Ancillary servicesIntegrated kidney care40-1921
Other—Ancillary servicesOther U.S. ancillary-8-6-13
Other—Ancillary servicesInternational253055
Other—Ancillary services57663
Other—Ancillary servicesCorporate administrative support expenses-16-30-46
Other—Ancillary servicesTotal consolidated operating income5794821,061

Income Statement

Three months ended — (dollars in millions and shares in thousands, except per treatment and patient data)

Three months ended – June 30, 2026Three months ended – March 31, 2026Six months ended June 30, 2026
Revenue:Dialysis patient service revenues3,0052,9355,941
Revenue:Other revenues7613
Revenue:Total operating revenues3,0122,9425,954
Operating expenses:Patient care costs2,0051,9693,974
Operating expenses:General and administrative331320651
Operating expenses:Depreciation and amortization146155302
Operating expenses:Equity investment income-8-8-16
Operating expenses:Total operating expenses2,4742,4364,910
Operating expenses:Segment operating income5385061,044
Volume:Treatments7,226,6007,029,52514,256,125
Volume:Number of treatment days7876.7154.7
Volume:Average treatments per day92,64991,65092,153
Volume:Per day year-over-year change0.6-0.20.2
Volume:Number of normalized treatment days(3)7876.5154.5
Volume:Average treatments per normalized day92,64991,88992,273

Income Statement

Twelve months ended

Twelve months ended – June 30, 2026June 30, 2026Twelve months ended – June 30, 2026June 30, 2026Twelve months ended – March 31, 2026March 31, 2026Twelve months ended – March 31, 2026March 31, 2026
Net income from continuing operations attributable to DaVita Inc.822756
Income taxes303305
Interest expense540535
Depreciation and amortization710717
Net income attributable to noncontrolling interests342340
Stock-settled stock-based compensation127136
Debt extinguishment and modification costs1614
Expected cost savings and expense reductions710
Other149194
Consolidated EBITDA3,0183,008
Total debt, excluding debt discount and other deferred financing costs(1)10,84810,694
Less: Cash and cash equivalents including short-term investments(2)-685-664
Consolidated net debt10,16210,031
Last twelve months Consolidated EBITDA3,0183,008
Leverage ratio3.37x3.34x
Maximum leverage ratio permitted under the Credit Agreement5.00x5.00x

Income Statement

Six months ended June 30, 2025 — There were no non-GAAP adjustments during the three and six months ended June 30, 2026 or the three months ended March 31, 2026.

Six months ended June 30, 2025 – U.S. dialysisSix months ended June 30, 2025 – Ancillary services – U.S. IKCSix months ended June 30, 2025 – Ancillary services – U.S. OtherSix months ended June 30, 2025 – Ancillary services – InternationalSix months ended June 30, 2025 – Ancillary services – TotalSix months ended June 30, 2025 – Corporate administrationSix months ended June 30, 2025 – Consolidated
Operating income (loss)999-3-106754-76977
Cybersecurity incident-related charges(1)1313
Adjusted operating income (loss)1,012-3-106754-76990

Income Statement

Three months ended — Effective income tax rates:

Three months ended – June 30, 2026Three months ended – March 31, 2026Six months ended June 30, 2026
Effective income tax rates on income attributable to DaVita Inc.:Income before income taxes435341776
Effective income tax rates on income attributable to DaVita Inc.:Noncontrolling owners’ income primarily attributable to non-tax paying entities-78-78-156
Effective income tax rates on income attributable to DaVita Inc.:Income before income taxes attributable to DaVita Inc.357264620
Effective income tax rates on income attributable to DaVita Inc.:Income tax expense9266158
Effective income tax rates on income attributable to DaVita Inc.:Income tax attributable to noncontrolling interests-1-1
Effective income tax rates on income attributable to DaVita Inc.:Income tax expense attributable to DaVita Inc.9166157
Effective income tax rates on income attributable to DaVita Inc.:Effective income tax rate on income attributable to DaVita Inc.25.625.125.4

Balance Sheet

June 30, 2026 — (dollars and shares in thousands, except per share data)

June 30, 2026December 31, 2025
ASSETSCash and cash equivalents668,963676,438
ASSETSRestricted cash and equivalents82,89581,309
ASSETSShort-term investments19,91424,303
ASSETSAccounts receivable2,467,0562,414,690
ASSETSInventories151,535160,627
ASSETSContract assets and other receivables565,566494,414
ASSETSPrepaid and other current assets149,113156,285
ASSETSIncome tax receivable84,59749,937
ASSETSTotal current assets4,189,6394,058,003
ASSETSProperty and equipment, net of accumulated depreciation of $6,867,296 and $6,602,134, respectively2,749,3082,812,966
ASSETSOperating lease right-of-use assets2,430,0552,397,179
ASSETSIntangible assets, net of accumulated amortization of $38,030 and $37,751, respectively228,817222,125
ASSETSEquity method and other investments183,801157,249
ASSETSLong-term investments38,36540,966
ASSETSOther long-term assets298,538246,520
ASSETSGoodwill7,590,9667,545,095
ASSETS17,709,48917,480,103
LIABILITIES AND EQUITYAccounts payable715,872696,148
LIABILITIES AND EQUITYOther liabilities826,995893,024
LIABILITIES AND EQUITYAccrued compensation and benefits694,766793,478
LIABILITIES AND EQUITYCurrent portion of operating lease liabilities439,488425,484
LIABILITIES AND EQUITYCurrent portion of long-term debt117,177109,201
LIABILITIES AND EQUITYIncome tax payable24,62124,359
LIABILITIES AND EQUITYDue to related party36,513199,940
LIABILITIES AND EQUITYTotal current liabilities2,855,4323,141,634
LIABILITIES AND EQUITYLong-term operating lease liabilities2,185,9732,175,658

Cash Flow

Six months ended June 30, — (dollars in thousands)

Six months ended June 30, – 2026Six months ended June 30, – 2025
Cash flows from operating activities:Net income618,258507,436
Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization345,637351,155
Adjustments to reconcile net income to net cash provided by operating activities:Stock-based compensation expense54,18962,567
Adjustments to reconcile net income to net cash provided by operating activities:Deferred income taxes53,431-9,838
Adjustments to reconcile net income to net cash provided by operating activities:Equity investment loss, net2,43747,730
Adjustments to reconcile net income to net cash provided by operating activities:Other non-cash losses, net16,7216,948
Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:Accounts receivable-24,197-288,447
Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:Inventories11,315-9,592
Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:Other current assets-58,339-70,945
Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:Other long-term assets-22,8032,981
Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:Accounts payable7,63935,612
Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:Accrued compensation and benefits-108,322-125,365
Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:Other current liabilities-55,837-3,586
Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:Income taxes-32,5309,462
Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:Other long-term liabilities3,301-11,873
Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:Net cash provided by operating activities810,900504,245
Cash flows from investing activities:Additions of property and equipment-271,836-264,349
Cash flows from investing activities:Acquisitions-38,540-10,596
Cash flows from investing activities:Proceeds from asset and business sales4,39222,400
Cash flows from investing activities:Purchase of debt investments held-to-maturity-298-27,475
Cash flows from investing activities:Purchase of other debt and equity investments-12,867-3,002
Cash flows from investing activities:Proceeds from debt investments held-to-maturity94248,014
Cash flows from investing activities:Proceeds from sale of other debt and equity investments4,3826,379
Cash flows from investing activities:Purchase of equity method investments-19,625-2,144
Cash flows from investing activities:Distributions from equity method investments1091,470
Cash flows from investing activities:Net cash used in investing activities-333,341-229,303
Cash flows from financing activities:Borrowings2,768,2594,189,716
Cash flows from financing activities:Payments on long-term debt-2,264,356-3,373,300
Cash flows from financing activities:Deferred and debt related financing costs-4,645-25,133
Cash flows from financing activities:Purchase of treasury stock from related party-382,805-200,261
Cash flows from financing activities:Other purchases of treasury stock-377,852-793,834
Cash flows from financing activities:Distributions to noncontrolling interests-149,892-151,087
Cash flows from financing activities:Net proceeds from issuance of common stock under employee stock plans5,9098,913
Cash flows from financing activities:Payment of tax withholdings on net share settlements of equity awards-63,814-30,477
Cash flows from financing activities:Contributions from noncontrolling interests4,2392,578
Cash flows from financing activities:Proceeds from sales of additional noncontrolling interests169
Cash flows from financing activities:Purchases of noncontrolling interests-18,571-5,378
Cash flows from financing activities:Net cash used in financing activities-483,528-378,094
Cash flows from financing activities:Effect of exchange rate changes on cash, cash equivalents and restricted cash8020,286
Cash flows from financing activities:Net decrease in cash, cash equivalents and restricted cash-5,889-82,866
Cash flows from financing activities:Cash, cash equivalents and restricted cash at beginning of the year757,747879,825
Cash flows from financing activities:Cash, cash equivalents and restricted cash at end of the period751,858796,959

Cash Flow

Three months ended — Free cash flow:

Three months ended – June 30, 2026Three months ended – March 31, 2026Three months ended – June 30, 2025Six months ended June 30, 2026
Net cash provided by operating activities490321324811
Adjustments to reconcile net cash provided by operating activities to free cash flow:Distributions to noncontrolling interests-64-85-58-150
Adjustments to reconcile net cash provided by operating activities to free cash flow:Contributions from noncontrolling interests44
Adjustments to reconcile net cash provided by operating activities to free cash flow:Maintenance capital expenditures(3)-123-74-90-197
Adjustments to reconcile net cash provided by operating activities to free cash flow:Development capital expenditures(4)-47-28-32-75
Adjustments to reconcile net cash provided by operating activities to free cash flow:Proceeds from sale of self-developed properties2122
Adjustments to reconcile net cash provided by operating activities to free cash flow:Free cash flow256140157396

Cash Flow

Twelve months ended — Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.

Twelve months ended – June 30, 2026Twelve months ended – March 31, 2026Twelve months ended – June 30, 2025
Net cash provided by operating activities2,1932,0271,862
Adjustments to reconcile net cash provided by operating activities to free cash flow:Distributions to noncontrolling interests-323-317-381
Adjustments to reconcile net cash provided by operating activities to free cash flow:Contributions from noncontrolling interests999
Adjustments to reconcile net cash provided by operating activities to free cash flow:Maintenance capital expenditures(3)-424-391-407
Adjustments to reconcile net cash provided by operating activities to free cash flow:Development capital expenditures(4)-159-144-167
Adjustments to reconcile net cash provided by operating activities to free cash flow:Proceeds from sale of self-developed properties122430
Adjustments to reconcile net cash provided by operating activities to free cash flow:Free cash flow1,3081,209947
Full release

DaVita Inc. and its representatives may from time to time make written and oral forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA), including statements in this release, filings with the Securities and Exchange Commission (SEC), reports to stockholders and in meetings with investors and analysts. All statements in this release, during the related presentation or other meetings, other than statements of historical fact, are forward-looking statements and as such are intended to be covered by the safe harbor for "forward-looking statements" provided by the PSLRA. These forward-looking statements could include, among other things, statements about our balance sheet and liquidity, our expenses, revenues, billings and collections, patient census, the impact of the cybersecurity incident experienced by the Company in 2025 (cyber incident), the impact of federal government policy changes or shutdowns on our business, including with respect to federal funding and reimbursement rates of Medicare, Medicare Advantage (MA), Medicaid and other government programs, availability or cost of supplies, including without limitation the impact of evolving trade policies and tariffs and any reduction in clinical and other supplies due to any disruptions experienced by third party vendors, including with respect to our ability to provide home dialysis services, treatment volumes, mix expectation, such as the percentage or number of patients under commercial insurance, including potential impacts to such mix as a result of U.S. administration policies, current macroeconomic, marketplace and labor market conditions, and overall impact on our patients and teammates, as well as other statements regarding our outlook, future operations, financial condition and prospects, capital allocation plans, expenses, cost saving initiatives, other strategic initiatives, use of contract labor, government and commercial payment rates, expectations related to value-based care (VBC), integrated kidney care (IKC), MA plan enrollment and our international operations, expectations regarding increased competition and marketplace changes, including those related to new or potential entrants in the dialysis and pre-dialysis marketplace and the potential impact of innovative technologies, drugs, or other treatments on the dialysis industry, and expectations regarding our share repurchase program. All statements in this release, other than statements of historical fact, are forward-looking statements. Without limiting the foregoing, statements including the words "expect," "intend," "will," "could," "plan," "anticipate," "believe," "forecast," "guidance," "outlook," "goals," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on DaVita's current expectations and are based solely on information available as of the date of this release. DaVita undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of changed circumstances, new information, future events or otherwise, except as may be required by law. Actual future events and results could differ materially from any forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things:

• external conditions, including those related to general economic, political and global health conditions, including without limitation, the impact of global events and political or governmental volatility, including in the Middle East; the impact of the domestic political environment and related developments on the current healthcare marketplace, our patients and on our business; the impact of infectious diseases or other adverse conditions on our financial condition, the chronic kidney disease population and our patient population; supply chain challenges and disruptions, including without limitation, with respect to certain key services, critical clinical supplies and equipment we obtain from third parties, and including any impacts on our supply chain and cost of supplies as a result of global events, natural disasters or evolving trade policies, including tariffs; the impact on our patients and industry of continued increased competition from dialysis providers and others, including new or potential entrants in the dialysis and pre-dialysis marketplace; the impact of new or innovative technologies, drugs, or other treatments, including our ability to successfully implement new technologies, treatments or therapies in our business such as those related to middle molecule toxin clearance; elevated teammate turnover or labor costs; and our ability to respond to challenging U.S. and global economic and marketplace conditions, including, among other things, our ability to successfully identify cost saving opportunities;

• the concentration of profits generated by higher-paying commercial payor plans for which there is continued downward pressure on average realized payment rates; our ability to negotiate and maintain contracts with these payors on competitive terms or at all; a reduction in the number or percentage of our patients under commercial plans, including, without limitation, as a result of healthcare, immigration or other policies implemented by the U.S. administration, continuing legislative efforts to restrict or prohibit the use and/or availability of charitable premium assistance, as a result of payors implementing restrictive plan designs or resulting from negotiations with large commercial payors that we have in the past, and currently are, conducting on a concurrent basis;

• risks arising from laws, regulations or requirements applicable to us or changes thereto, including, without limitation, OBBBA and those related to trade policy, healthcare, privacy, antitrust matters, and acquisition, merger, joint venture or similar transactions and/or labor matters, and potential impacts of changes in interpretation or enforcement thereof or related litigation impacting, among other things, coverage or reimbursement rates for our services or the number of patients enrolled in or that select higher-paying commercial plans, and the risk that we make incorrect assumptions about how our patients will respond to any such developments;⁴

• our ability to successfully implement our strategies with respect to IKC and VBC initiatives that may be impacted by, among other things, changes to the Comprehensive Kidney Care Contracting model and home based dialysis in the desired time frame and in a complex, dynamic and highly regulated environment;

• a reduction in government payment rates under the Medicare End Stage Renal Disease program, state Medicaid or other government-based programs and the impact of the MA benchmark structure and adjustment methodologies;

• our reliance on significant suppliers, service providers and other third party vendors to provide key support to our business operations and enable our provision of services to patients, including, among others, suppliers of certain pharmaceuticals, administrative or other services or critical clinical products; and risks resulting from a closure, reduction, disruption or transition in the services or products provided to us by such suppliers, service providers and third party vendors, which may, among other things, increase our costs or expenses;

• our ability to successfully maintain, operate or upgrade our information systems or those of third-party service providers upon which we rely and our ability to successfully adopt or adapt to new technologies, treatments or therapies, including technologies that utilize artificial intelligence;

• legal and compliance risks, such as compliance with complex, and at times, evolving government regulations and requirements, and with additional laws that may apply to our operations as we expand geographically or enter into new lines of business;

• noncompliance by us or our business associates with any privacy or security laws or any security breach by us or a third party, such as the cyber incident, including, among other things, any such non-compliance or breach involving the misappropriation, loss or other unauthorized use or disclosure of confidential information;

• our ability to attract, retain and motivate teammates, including key leadership personnel, our ability to manage potential disruptions to our business and operations, including potential work stoppages, and our ability to manage operating cost increases or productivity decreases that may be related to political unrest, legislative or other changes, union organizing activities, or volatility and uncertainty in the current challenging and highly competitive labor market that has experienced an ongoing nationwide shortage of skilled clinical personnel, among other things;

• changes in practice patterns, pricing, or reimbursement and payment policies or processes related to pharmaceuticals, medical equipment or supplies, including with respect to oral phosphate binders, among other things;

• our ability to develop and maintain relationships with physicians and hospitals, changing affiliation models for physicians, and the emergence of new models of care or other initiatives that, among other things, may erode our patient base and impact reimbursement rates;

• our ability to complete and successfully integrate and operate acquisitions, mergers, dispositions, joint ventures or other strategic transactions on terms favorable to us or at all; and our ability to continue to successfully expand our operations and services in markets outside the United States, or to businesses or products outside of dialysis services;

• the variability of our cash flows, including, without limitation, any extended billing or collections cycles that may be due to, among other things, defects or operational issues in our billing systems such as those experienced during the cyber incident, or defects or operational issues in the billing systems or services of third parties on which we rely; the risk that we may not be able to generate or access sufficient cash in the future to service our indebtedness or to fund our other liquidity needs;

• the effects on us or others of natural or other disasters, public health crises or severe adverse weather events such as hurricanes, earthquakes, fires or flooding;

• factors that may impact our ability to repurchase stock under our share repurchase program and the timing of any such stock repurchases, as well as any use by us of a considerable amount of available funds to repurchase stock;

• ... (truncated)orting requirements; and

• the other risk factors, trends and uncertainties set forth in our Annual Report on Form 10-K for the year ended December 31, 2025 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, and the risks and uncertainties discussed in any subsequent reports that we file or furnish with the SEC from time to time.

The financial information presented in this release is unaudited and is subject to change as a result of subsequent events or adjustments, if any, arising prior to the filing of the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.⁵

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Davita earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.